Sep 27, 2021

Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech

Cambridge, MA – September 27, 2021 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced it has been …

Learn More

Sep 01, 2021

Ribon Therapeutics Announces Key Management Promotions

Heike Keilhack, Ph.D., Promoted to Chief Scientific Officer Kevin Kuntz, Ph.D., Promoted to Chief Drug Development Officer Cambridge, MA – September 1, 2021 – Ribon …

Learn More

Jul 22, 2021

Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397

Small molecule inhibitor of PARP7 restores Type I interferon signaling in tumor cells Data validate therapeutic strategy of targeting PARP7, a key vulnerability in cancer …

Learn More

Jul 14, 2021

Ribon Therapeutics Secures $65 Million Financing

Proceeds Support Advancement of Lead Product Candidates RBN-2397 and RBN-3143 Through Key Clinical Milestones Cambridge, MA – July 14, 2021 – Ribon Therapeutics, a clinical …

Learn More

Jun 28, 2021

Ribon Therapeutics Appoints Paul Brannelly as Chief Financial Officer

Cambridge, MA – June 28, 2021 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the appointment of …

Learn More

Jun 04, 2021

Ribon Therapeutics Announces Oral Presentation of Positive Interim Data from Phase 1 Trial of RBN-2397 in Patients with Advanced Solid Tumors at 2021 ASCO Annual Meeting

RBN-2397 was well tolerated and demonstrated evidence of target inhibition and preliminary signs of clinical activity One partial response (PR) and nine patients with stable …

Learn More

May 20, 2021

Ribon Therapeutics Announces Oral Presentation of RBN-2397 Clinical Data at 2021 ASCO Annual Meeting

Cambridge, MA – May 20, 2021 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that data from …

Learn More

Apr 29, 2021

Ribon Therapeutics Announces Upcoming Presentation on RBN-2397 at the 2021 ASCO Annual Meeting

CAMBRIDGE, Mass. – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced an oral presentation on RBN-2397 at the …

Learn More

Apr 06, 2021

Ribon Therapeutics Announces Upcoming Presentations at the AACR 2021 Virtual Annual Meeting

Cambridge, MA – April 6, 2021 – Ribon Therapeutics, a clinical stage oncology company developing therapeutics targeting stress support pathways, today announced that it will …

Learn More

Feb 02, 2021

Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries

– Ono to make upfront payment of approximately $16.3 million to Ribon in addition to other potential milestone payments of approximately $132 million    Cambridge, …

Learn More

Nov 16, 2020

Ribon Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Cambridge, MA – November 16, 2020 – Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria …

Learn More

Nov 09, 2020

Ribon Therapeutics Announces the Appointment of Emma Reeve to the Company’s Board of Directors

Cambridge, MA – November 9, 2020 – Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced the appointment of …

Learn More

Jul 16, 2020

Ribon Therapeutics Announces Appointment of Jodie P. Morrison as Chair of the Company’s Board of Directors

Cambridge, MA – July 16, 2020 – Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Jodie P. …

Learn More

Jun 22, 2020

Ribon Therapeutics Presents Additional Preclinical Data on its PARP7 Inhibitor – RBN-2397 – and Demonstrates Broad Potential of its Platform at the AACR 2020 Virtual Meeting II

-Reinforces PARP7 as a novel therapeutic target and that inhibition of PARP7 induces both antitumor immunity and cancer cell-intrinsic effects– -Platform identifies several cancer-relevant monoPARPs …

Learn More

May 26, 2020

Ribon Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Cambridge, MA – May 26, 2020 – Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria …

Learn More

May 15, 2020

Ribon Therapeutics to Present New Preclinical Data on its PARP7 Inhibitor – RBN-2397 – and its Discovery Platform at the Upcoming AACR 2020 Virtual Meeting II

-RBN-2397 restores type I IFN signaling in the tumor, causes complete tumor regressions and adaptive immunity in preclinical models- Cambridge, MA – May 15, 2020 …

Learn More

May 04, 2020

Ribon Therapeutics to Present at Upcoming Healthcare Conferences

Cambridge, MA – May 4, 2020 — Ribon Therapeutics, a clinical-stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria Richon, …

Learn More

Apr 27, 2020

Ribon Therapeutics Presents Preclinical Data from its PARP7 and PARP14 Programs at AACR Virtual Meeting I

— Lead program, PARP7 inhibitor RBN-2397, demonstrates complete tumor regression in preclinical cancer models — — Phase 1 study underway evaluating RBN-2397 in advanced-stage solid …

Learn More

Apr 14, 2020

Ribon Therapeutics to Present New Preclinical Data at the Upcoming AACR Virtual Annual Meetings

Cambridge, MA – April 14, 2020 – Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced the presentation …

Learn More

Jan 24, 2020

Ribon Therapeutics to Present at Upcoming Scientific Conferences

Cambridge, MA – Jan. 24, 2020 – Ribon Therapeutics, a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress …

Learn More

Jan 06, 2020

Ribon Therapeutics Named as a Top Life Sciences Company to Watch in 2020

BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life sciences companies in North America…

Learn More

Dec 18, 2019

Ribon Therapeutics Strengthens Scientific Advisory Board with Appointment of Neal Rosen, M.D., Ph.D.

Cambridge, MA – Dec. 18, 2019 – Ribon Therapeutics, a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress …

Learn More

Sep 04, 2019

Ribon Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of RBN-2397, a First-In-Class PARP7 Inhibitor

PARP7 is a Novel Tumor Dependency, Enabling Cancer Cells to Evade the Immune System First Ever Clinical Evaluation of a monoPARP Inhibitor Cambridge, MA – …

Learn More

Aug 06, 2019

Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business Officer

Cambridge, MA – Aug. 6, 2019 – Ribon Therapeutics, a clinical stage biotechnology company, developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress …

Learn More

Jan 04, 2019

Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer

Financing led by the Novartis Venture Fund, with Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Celgene, and existing investors, The Column Group, Deerfield Management, …

Learn More
Join our team of experts.
Find Out More